Is P&G’s pharma business for sale?
A sale of Procter & Gamble's pharma business could fetch more than $1 billion, according to an estimate by one analyst. That's revenue P&G could reinvest in its core business areas, beauty and consumer health care. Reports that P&G's Rx business is up for sale began circulating the week of Feb. 2. Sources say the company has indeed hired Goldman Sachs to facilitate a sale of the business, although P&G dismissed the reports as "total speculation." News of a potential sale hardly comes as a surprise after P&G announced in December that the company was halting investment in pharmaceuticals and reducing headcount in its 2,900-person pharmaceutical workforce by 6 percent to 7 percent to focus on more profitable businesses, including oral care and consumer health care (1"The Pink Sheet," Dec. 22, 2008, p. 9). Potential buyers could include P&G's existing partners: Sanofi-Aventis on Actonel and Novartis on Enablex
You may also be interested in...
Procter & Gamble is moving away from pharmaceuticals to focus on more profitable businesses, such as oral care and consumer healthcare
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.